Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520901 | 1.00 | CYP19A1 (0.72) | CYP19A1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4759593 | 0.84 | CYP19A1 (0.70) | CYP19A1CRBNCXCR3 | |
| SCHEMBL10530071 | 0.84 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL22623727 | 0.84 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL8245665 | 0.84 | CYP19A1 (0.70) | CYP19A1CRBNCXCR3 | |
| Cyproximide SCHEMBL121879 | 0.84 | CYP19A1 (0.70) | CYP19A1SLC6A2SLC6A4SLC6A3MAOB | |
| SCHEMBL13201868 | 0.84 | CYP19A1 (0.70) | CYP19A1CRBNCXCR3 | |
| SCHEMBL10530941 | 0.84 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL2054565 | 0.83 | CYP19A1 (0.69) | CYP19A1KCNH2MAOBMAOACXCR3 | |
| SCHEMBL1552771 | 0.83 | CYP19A1 (0.69) | CYP19A1KCNH2MAOBMAOACXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | DOV PHARMACEUTICAL, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1807071-A4 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1807071-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV Pharmaceutical Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-7094799-B2 | A single, thermodynamical stable crystal structure, is crystallized from a cooled and agitated solvent solution, analgesic drug for reducing pain | DOV PHARMACEUTICAL, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| WO-2006050520-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | EUTHYMICS BIOSCIENCE, INC. | 2004-05-27 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4118417-A | Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | CYP19A1 1368/4885SLC6A2 1404/4885SLC6A4 783/4885 |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | CYP19A1 1368/4885SLC6A2 1404/4885SLC6A4 783/4885 |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | CYP19A1 1368/4885SLC6A2 1404/4885SLC6A4 783/4885 |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | BPHL, MYOF, NISCH | CYP19A1 2167/4885SLC6A2 625/4885SLC6A4 1813/4885 |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | CYP19A1 1884/4885SLC6A2 1776/4885SLC6A4 1519/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | CYP19A1 29/4885SLC6A2 1744/4885SLC6A4 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.